Biogen’s Alzheimer’s drug is back from the dead

Biogen's Alzheimer's drug is back from the dead

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

From Biogen, the first drug to actually slow the decline of Alzheimer’s disease, rather than just ameliorate the symptoms, is alive and seeking FDA approval.

Longevity.Technology: There aren’t often Breaking News stories in drugs research. Rather it’s a slow process of clinical trials, data review and approval after approval. However, Biogen’s complete change of position on its drug aducanumab is proper headline stuff. Will it go down in Longevity history as our equivalent of the Post-It note, or penicillin?
In an astonishing about-face, Biogen and its partners at Eisai, have revealed that after completing the analysis of a larger set of data on aducanumab, they have renewed faith in their Alzheimer’s drug and are submitting it to the FDA in the US for regulatory approval.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Eleanor Garth

Editor

Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.

With a keen interest in all things geroscience, Eleanor covers the biological mechanisms of aging, highlighting how interventions – from nutritional strategies to advanced therapeutics – can influence the aging process at a cellular level. She also investigates the broader implications of aging research, including the integration of longevity science into healthcare strategy and the expanding wellness economy. Her work (hopefully) provides insights into how these developments are shaping the emerging landscape of healthspan optimization and age-related innovation.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Novartis exits a BioArctic deal worth up to $802m

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE